ABSTRACT
PURPOSE OF REVIEW: Psychosis is a psychiatric condition that has significant overlap with neurologic disease. This article is intended to educate the neurologist on the psychiatric manifestations of psychosis and its evaluation, diagnosis, and treatment. How to differentiate a primary psychiatric cause of psychosis from psychosis secondary to a medical or neurologic condition is also reviewed. RECENT FINDINGS: Current research in psychotic disorders has focused increasingly on negative symptoms and cognitive impairment in psychotic illness, as it is now recognized that these cause the greatest impact on functional deficits for patients. A number of new medications have also been introduced to target negative symptoms and cognitive deficits in psychotic illness. These have new implications in terms of treatment overlap with medications being prescribed by providers in psychiatry, neurology, and general practice. SUMMARY: This article discusses the current methods for evaluating, diagnosing, and treating psychosis. Psychosis as a primary mental health disorder is a diagnosis of exclusion, as psychosis can be a direct symptom of underlying medical or neurologic disease. Delirium and dementia are the two most important disorders to rule out. This article will help readers be more prepared to assess and treat the patient with psychosis.
Subject(s)
Psychotic Disorders/diagnosis , Psychotic Disorders/therapy , HumansABSTRACT
Bipolar I disorder is a serious and disabling psychiatric illness. It is associated with a significant reduction in quality of life and an increased risk for suicide. Pharmacotherapy is essential for both the acute and maintenance treatment of bi-polar I disorder. While multiple oral medications are recommended for the maintenance treatment, there are not many long-acting injectable medications approved for this indication. New treatments that would improve patient adherence have the potential for decreasing relapses and improving patients' ability to remain functional members of society. In this paper we discuss the available data for safety and efficacy of aripiprazole long-acting injectable in bipolar disorder.
Subject(s)
Antipsychotic Agents/pharmacology , Aripiprazole/pharmacology , Bipolar Disorder/drug therapy , Adult , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , Aripiprazole/administration & dosage , Aripiprazole/adverse effects , Delayed-Action Preparations , Humans , InjectionsABSTRACT
OBJECTIVE: The authors assessed the relationship between Emotional Intelligence (EI) and Psychiatry Resident In-Training Exam (PRITE) scores. EI is important to the therapeutic alliance. The hypothesis tested was that PRITE scores would correlate with EI. METHOD: Adult Psychiatry residents participated. The PRITE was administered, and participants completed the online Bar-On Emotional Intelligence Quotient questionnaire. RESULTS: Pearson correlation coefficients were calculated for PRITE score and overall EI score, and with the 15 EI subscales. The correlation for PRITE and overall EI was not significant. Three EI subscales had statistically significant correlations with PRITE score: empathy, social responsibility, and impulse control. CONCLUSIONS: There was no significant correlation between overall EI and PRITE scores. There was an inverse relationship between PRITE scores and empathy, social responsibility, and impulse control. The authors discuss possible explanations for these relationships.
